Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

Erratum to: Invest New Drugs

DOI 10.1007/s10637-011-9687-4

An error has occurred during production of this article. In Table 1 the published version states: selumetinib, n = 32; capecitabine, n = 38. This should be: selumetinib, n = 38; capecitabine, n = 32. The correct Table 1 is also shown on the next page.

Table 1 Patient demographics and baseline characteristics (intent-to-treat population)